ADVERTISEMENT

Advanced HCC: the best options for first-line therapy vs refractory disease

Jim Kling   |   Clinical Summary   |   02 November 2020
ADVERTISEMENT

Takeaway

  • The results of this network meta-analysis suggest that the best choice for first-line advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab.
  • Regorafenib and cabozantinib are best in refractory disease.

Why this matters

  • The results suggest that these options should be the standard of care in the respective settings. 

Study design

  • Network...

          

Topic Challenges

left
right